scispace - formally typeset
A

Antonio Craxì

Researcher at University of Palermo

Publications -  699
Citations -  44773

Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.

Papers
More filters
Journal ArticleDOI

Impact of COVID-19 on global HCV elimination efforts.

TL;DR: The impact of COVID-19 extends beyond the direct morbidity and mortality associated with exposure and infection to mitigate the impact on viral hepatitis programming and reduce excess mortality from delayed treatment, policy makers should prioritize hepatitis programs as soon as it becomes safe to do so.
Journal ArticleDOI

Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma.

TL;DR: The Italian Association for the Study of the Liver expert panel recommendations are reported, aiming to provide: (1) homogeneous and efficacious diagnostic and staging work-up, and (2) the best treatment choice tailored to patient status and tumour stage at diagnosis.
Journal ArticleDOI

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.

Sarah Blach, +257 more
TL;DR: In this article , a literature review, Delphi process, and mathematical modelling were used to estimate hepatitis C virus (HCV) prevalence (viraemic infection, defined as HCV RNA-positive cases) and the cascade of care among people of all ages (age ≥ 0 years from birth) for the period between Jan 1, 2015 and Dec 31, 2030.
Journal ArticleDOI

Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease

TL;DR: Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non‐alcoholic fatty liver disease (NAFLD).